With respect to receptor tyrosine kinases (RTKs), phase III nimotuzumab trial (ENRICH) and rilotumumab trial (RILOMET-1) for epidermal growth factor receptor (EGFR)- and MET-positive GC are under investigation (ClinicalTrials.gov Identifier, NCT01813253 and NCT01697072). Here, NTRK1 is linked to gastric cancer.